Selecting the optimal treatment for patients with chronic myeloid leukaemia after two prior lines of therapy

touchPODCAST

Nov 3 2022 • 29 mins

touchIN CONVERSATION for touchONCOLOGY

Listen to two chronic myeloid leukaemia experts, Prof. Simona Soverini and Dr Daniela Žáčková  discuss the mechanisms of action and latest data for new and emerging treatment options for patients with chronic myeloid leukaemia after two prior lines of therapy, and how they might impact the management of chronic myeloid leukaemia. The discussion is guided by pre-canvassed questions from the chronic myeloid leukaemia clinical community.

This touchPODCAST is intended for non-UK and non-US HCPs only.

This activity is funded by an unrestricted independent medical education grant from Novartis and is provided by touchIME.

For further information visit our website touchONCOLOGY